Berlin, Germany
FyoniBio GmbH is a German startup providing smart solutions to accelerate biopharmaceutical development from target-to-clinic. As a contract development organization and clinical laboratory, FyoniBio offers custom-tailored services at different drug development stages to pharmaceutical and biotechnology companies. With ISO-9001:2015 fully-integrated services, the company specializes in drug glycosylation, a critical quality attribute of biopharmaceuticals affecting various aspects of drug efficacy and safety. FyoniBio's human GlycoExpress cells and the CHO platform technology CHOnamite are key components in addressing these challenges, complemented by a service portfolio featuring GCLP-compliant bioanalysis of clinical samples.
Founded in 2021, FyoniBio leverages 20 years of experience to offer comprehensive services ranging from cell line engineering to process development and drug quality control, as well as broad bioanalytical capabilities for preclinical and clinical studies. The company's focus on drug glycosylation, coupled with upstream and downstream process optimization, state-of-the-art equipment, and in-house developed software for glycan analytics, positions it as an innovative player in the biotechnology and pharmaceutical industries.
